Premium
Effects of dihydromyricetin on ARPE‐19 cell migration through regulating matrix metalloproteinase‐2 expression
Author(s) -
Wang Kai,
Yang ShunFa,
Hsieh YiHsien,
Chang YuanYen,
Yu NuoYi,
Lin HuiWen,
Lin HungYu
Publication year - 2018
Publication title -
environmental toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.813
H-Index - 77
eISSN - 1522-7278
pISSN - 1520-4081
DOI - 10.1002/tox.22637
Subject(s) - matrix metalloproteinase , western blot , cell migration , extracellular matrix , proliferative vitreoretinopathy , matrix metalloproteinase inhibitor , microbiology and biotechnology , p38 mitogen activated protein kinases , chemistry , cell , cell growth , kinase , protein kinase a , cancer research , biology , biochemistry , retinal , gene , retinal detachment
Dihydromyricetin (DHM), a flavanonol compound in Ampelopsis grossedentata , possesses several biological activities. However, the molecular mechanism underlying the effects of DHM on human proliferative vitreoretinopathy (PVR) remains unclear. We explored the effects of DHM on cell migration and the metastasis‐promoting proteins in human retinal pigment epithelial (RPE) cells (ARPE‐19 cells). Our results revealed that DHM attenuated ARPE‐19 cell invasion and migration by reducing matrix metalloproteinase‐2 (MMP‐2) expression. Furthermore, a Western blot analysis revealed that DHM significantly reduced levels of phosphorylated c‐Jun N ‐terminal kinase 1/2, but not those of extracellular signal‐regulated kinase 1/2 and p38. In conclusion, our findings shown that DHM inhibits human RPE cell migration through the inhibition of MMP‐2 expression; therefore, DHM may have potential therapeutic value in treating PVR as adjuvant therapy.